KM257 Bispecific antibody
Phase 1Biologic
KM257 Bispecific antibody is one of 12 biologic programs targeting HER2 Positive. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in HER2 Positive
#DrugCompanyPhaseTrials
1Zaniducla
Jazz PharmaceuticalsPhase 2
Eloxatin
TevaPhase 2
Gemzar
Johnson & JohnsonPhase 2
Beyfortus
BeiGenePhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
S-1
Taiho Oncology, Inc.Phase 2
Tisleizumab(bgb-A317)
SSun Yat-sen University
Phase 2
T-Dxd
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KM257 Bispecific antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details